A108 USTEKINUMAB IV INDUCTION RESULTS IN CROHN’S DISEASE SYMPTOM IMPROVEMENT WITHIN THE FIRST WEEK IN ANTI-TNF REFRACTORY PATIENTS

BACKGROUND: In both the UNITI-1&2 Crohn’s disease (CD) studies, a single 6mg/kg Ustekinumab (UST) IV infusion showed significantly greater rates of clinical response & remission vs placebo, and significant reductions in CDAI (and >70 pt reduction)(1) by the first post-baseline visit at Wk...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Can Assoc Gastroenterol
Hlavní autoři: Sandborn, W, Yeager, B, Gasink, C, Hoops, T, Gao, L, Wang, Y, Jacobstein, D, Lee, S D, Hanauer, S
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2018
Témata:
Paper Sessions
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6508147/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy009.108
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky